Literature DB >> 14695191

Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system.

Alexander V Kazansky1, David M Spencer, Norman M Greenberg.   

Abstract

The constitutive activation of signal transducer and activator of transcription (STAT) proteins has been demonstrated in many diverse human cancer cell lines and clinical tumors including prostate cancer. The STAT family has at least seven members, and the two forms of the STAT5 protein, STAT5A and STAT5B, exhibit a high degree of sequence similarity. We have reported previously that expression of STAT5B, but not STAT5A, could enhance the transforming potential of v-src and induces cell cycle progression and motility in fibroblasts. In the current study we demonstrate specific activation of STAT5B in epithelial cells representing invasive and metastatic prostate cancer. We also demonstrate that the naturally occurring dominant-negative isoform STAT5DeltaB can block cell cycle progression through G(1) and inhibit the growth, invasive potential, and clonogenic ability of these prostate cancer cell lines. Furthermore, we report that the dominant-negative isoform STAT5DeltaB can inhibit the growth of prostate cancer cells in grafting studies. These results support our hypothesis that specific activation of STAT5, in particular STAT5B, facilitates the progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695191

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Authors:  Tuomas Mirtti; Benjamin E Leiby; Junaid Abdulghani; Elina Aaltonen; Miia Pavela; Anita Mamtani; Kalle Alanen; Lars Egevad; Torvald Granfors; Andreas Josefsson; Par Stattin; Anders Bergh; Marja T Nevalainen
Journal:  Hum Pathol       Date:  2012-09-29       Impact factor: 3.466

Review 2.  Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.

Authors:  Mateusz Koptyra; Shilpa Gupta; Pooja Talati; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2011-06-17       Impact factor: 5.085

3.  Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications.

Authors:  Haiyan Yang; Li-Rong Yu; Ming Yi; David A Lucas; Luanne Lukes; Mindy Lancaster; King C Chan; Haleem J Issaq; Robert M Stephens; Thomas P Conrads; Timothy D Veenstra; Kent W Hunter
Journal:  J Proteome Res       Date:  2006-07       Impact factor: 4.466

4.  Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.

Authors:  Pradeep Sathyanarayana; Madhu P Menon; Olga Bogacheva; Oleg Bogachev; Knut Niss; William S Kapelle; Estelle Houde; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2007-04-02       Impact factor: 22.113

5.  Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Authors:  Zhiyong Liao; Lei Gu; Jenny Vergalli; Samanta A Mariani; Marco De Dominici; Ravi K Lokareddy; Ayush Dagvadorj; Puranik Purushottamachar; Peter A McCue; Edouard Trabulsi; Costas D Lallas; Shilpa Gupta; Elyse Ellsworth; Shauna Blackmon; Adam Ertel; Paolo Fortina; Benjamin Leiby; Guanjun Xia; Hallgeir Rui; David T Hoang; Leonard G Gomella; Gino Cingolani; Vincent Njar; Nagarajan Pattabiraman; Bruno Calabretta; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2015-05-29       Impact factor: 6.261

6.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

7.  Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

Authors:  Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2019-09-23       Impact factor: 6.261

8.  A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrin-mediated human breast cancer cell migration.

Authors:  Teresa M Bernaciak; Jessica Zareno; J Thomas Parsons; Corinne M Silva
Journal:  Breast Cancer Res       Date:  2009-07-24       Impact factor: 6.466

9.  Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Authors:  Pooja G Talati; Lei Gu; Elyse M Ellsworth; Melanie A Girondo; Marco Trerotola; David T Hoang; Benjamin Leiby; Ayush Dagvadorj; Peter A McCue; Costas D Lallas; Edouard J Trabulsi; Leonard Gomella; Andrew E Aplin; Lucia Languino; Alessandro Fatatis; Hallgeir Rui; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2015-09       Impact factor: 4.307

Review 10.  The different functions of Stat5 and chromatin alteration through Stat5 proteins.

Authors:  Jan-Wilhelm Kornfeld; Florian Grebien; Marc A Kerenyi; Katrin Friedbichler; Boris Kovacic; Barbara Zankl; Andrea Hoelbl; Harini Nivarti; Hartmut Beug; Veronika Sexl; Mathias Muller; Lukas Kenner; Ernst W Mullner; Fabrice Gouilleux; Richard Moriggl
Journal:  Front Biosci       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.